Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth. LONDON, Ma ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...